208 related articles for article (PubMed ID: 31967340)
1. Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and Vomiting.
Momper JD; Heinrichs MT; Krudys K; Griebel D; Kumar S; Kim I; Mehrotra N; Mulberg AE; Garimella N; Nelson R; Reaman G; Sinha V; Yao L; Zineh I; Burckart G; Sachs H; Mulugeta Y
J Clin Pharmacol; 2020 Jun; 60(6):775-784. PubMed ID: 31967340
[TBL] [Abstract][Full Text] [Related]
2. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
[TBL] [Abstract][Full Text] [Related]
3. Palonosetron versus Granisetron in Combination with Aprepitant and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Chemotherapy: A Single-Institutional Retrospective Cohort Study.
Miyoshi T; Miyashita H; Matsuo N; Odawara M; Hori M; Hiraki Y; Kawanaka H
Biol Pharm Bull; 2021; 44(10):1413-1418. PubMed ID: 34602550
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
5. Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Baron-Hay S; Aapro M; Bernareggi A; Schwartzberg L
Support Care Cancer; 2019 Apr; 27(4):1309-1317. PubMed ID: 30685793
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.
Gamble M; Carroll E; Wright GC; Glode AE
J Oncol Pharm Pract; 2020 Dec; 26(8):1964-1969. PubMed ID: 32633661
[TBL] [Abstract][Full Text] [Related]
7. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.
Tsuji D; Suzuki K; Kawasaki Y; Goto K; Matsui R; Seki N; Hashimoto H; Hama T; Yamanaka T; Yamamoto N; Itoh K
Support Care Cancer; 2019 Mar; 27(3):1139-1147. PubMed ID: 30094732
[TBL] [Abstract][Full Text] [Related]
8. Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study.
Araz M; Karaagac M; Korkmaz L; Koral L; Inci F; Beypinar I; Uysal M; Artac M
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1091-1097. PubMed ID: 30963213
[TBL] [Abstract][Full Text] [Related]
9. Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy.
Uchida M; Nakamura T; Makihara Y; Suetsugu K; Ikesue H; Mori Y; Kato K; Shiratsuchi M; Hosohata K; Miyamoto T; Akashi K
Pharmazie; 2018 May; 73(5):304-308. PubMed ID: 29724299
[TBL] [Abstract][Full Text] [Related]
10. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
Schwartzberg L; Barbour SY; Morrow GR; Ballinari G; Thorn MD; Cox D
Support Care Cancer; 2014 Feb; 22(2):469-77. PubMed ID: 24141698
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
[TBL] [Abstract][Full Text] [Related]
13. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial.
Xiong J; Zhao G; Yang S; Chen J
Adv Ther; 2019 Feb; 36(2):355-364. PubMed ID: 30607545
[TBL] [Abstract][Full Text] [Related]
15. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.
Navari RM
Expert Opin Drug Saf; 2020 Feb; 19(2):205-210. PubMed ID: 31709853
[No Abstract] [Full Text] [Related]
16. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
17. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
18. Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
Tan J; Wang S; Liang X; Li CC; Zhang J; Zhao Z; Kong XR; Deng X; Peng L; Yang C
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28941006
[TBL] [Abstract][Full Text] [Related]
19. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
Kovács G; Wachtel AE; Basharova EV; Spinelli T; Nicolas P; Kabickova E
Lancet Oncol; 2016 Mar; 17(3):332-344. PubMed ID: 26795844
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of antiemesis effects of granisetron, aprepitant and dexamethasone to palonosetron, aprepitant and dexamethasone in treatment of high-emetic risk chemotherapy-induced nausea and vomiting - a retrospective study for efficacy and safety in a single institute].
Osawa H; Goto H; Myojo T
Gan To Kagaku Ryoho; 2013 May; 40(5):617-21. PubMed ID: 23863585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
